Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive ...

The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

(AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with ...

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval for their second antibody-drug conjugate (ADC) cancer treatment, Datroway, the partners have secured a seventh nod for their ...

Kimco Realty Corp. Dep. Pfd. (Rep. 1/1000th 5.25% Cum. Redeem. Pfd. Series M)-1.13% Kimco Realty Corp. Dep. Pfd. (Rep. 1/1000th Pfd. Cl L)-1.27% Federal Realty Investment Trust Dep. Pfd. (Rep. 1 ...

Berkshire Hathaway Inc. Cl A-0.05% $1.01T Berkshire Hathaway Inc. Cl B-0.15% $1.01T VF Corp.-3.87% $10.35B Under Armour Inc. Cl C 0.68% $3.35B Under Armour Inc. Cl A 1.36% $3.35B ...

An AstraZeneca and Daiichi Sankyo drug designed to replace chemotherapy was cleared by US regulators for broader use in late-stage breast cancer patients. The Food and Drug Administration ...

Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D projects transferred to other areas of the Japanese group. It's ...

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years after being rejected by ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...